Loading...
•
Jun 30
STERIS Q1 2026 Earnings Report
STERIS delivered solid Q1 2026 results, achieving strong revenue and earnings growth across all major segments.
Key Takeaways
STERIS reported $1.39 billion in revenue and $177.4 million in net income for Q1 2026. EPS was $1.79 and adjusted EPS reached $2.34. All three core segments contributed to top-line growth, led by strong performance in Healthcare and Applied Sterilization Technologies (AST).
Revenue rose to $1.39 billion, an 8.7% increase year-over-year.
Net income attributable to shareholders was $177.4 million.
Free cash flow increased to $326.5 million, supporting continued investment and shareholder returns.
Healthcare and AST segments saw double-digit revenue and operating income growth.
STERIS
STERIS
STERIS Revenue by Segment
STERIS Revenue by Geographic Location
Revenue by Segment
Healthcare Revenue
CapyFin.comAST Revenue
CapyFin.comLife Sciences Revenue
CapyFin.comRevenue by Geographic Location
Ireland Revenue
CapyFin.comUnited States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
STERIS reaffirmed its full-year FY2026 outlook with adjusted EPS projected between $9.90 and $10.15, supported by strong organic growth and operating leverage.
Positive Outlook
- Raised dividend and delivered strong free cash flow of $326.5 million
- Healthcare segment maintained double-digit service growth
- Continued backlog growth in Healthcare and Life Sciences
- Strong earnings leverage with 8.7% top-line growth translating to 25.5% net income growth
- Reaffirmed FY26 adjusted EPS guidance of $9.90–$10.15
Challenges Ahead
- Life Sciences service growth was modest at 3.4%
- Currency exchange movements slightly dampened revenue growth
- Capital expenditures remained high at $93.6 million
- Healthcare backlog growth may indicate longer fulfillment cycles
- Macroeconomic pressures remain a risk for equipment sales
Revenue & Expenses
Visualization of income flow from segment revenue to net income